LC-MS/MS Method Development and Validation for Quantification of Lenvatinib in K2EDTA Human Plasma: A Comprehensive Review
Keywords:
Lenvatinib, LC-MS/MS, K₂EDTA plasma, bioanalytical method validation, ICH M10, therapeutic drug monitoring, tyrosine kinase inhibitorAbstract
Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET and KIT, used in radioiodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial carcinoma. Its pharmacokinetics vary widely between patients, more than 60% of patients need dose reduction or interruption, and exploratory trough targets of about 40–90 ng/mL have been proposed. These features have driven the development of LC-MS/MS methods for plasma quantification in support of clinical pharmacology and therapeutic drug monitoring (TDM).
This review surveys the bioanalytical methods published for lenvatinib between 2012 and 2026. It covers single-analyte LC-MS/MS methods in plasma and serum, the sponsor's multi-laboratory validation and cross-validation, multi-analyte TKI panels, methods for total and unbound drug, microsampling (dried blood spots), HPLC-UV and preclinical methods. For each, sample volume, anticoagulant, extraction, internal standard, chromatography, MS transitions, calibration range and validation findings are summarised.
The literature shows that protein precipitation with a stable-isotope-labelled internal standard and a short C18 gradient can meet TDM needs over 0.5–2000 ng/mL. However, most methods used sodium-heparin plasma, only one plasma method reports K₂EDTA, several calibration ranges do not bracket the clinical trough window, matrix effects are often large, and no single-analyte method has been validated under ICH M10. A strategy for a K₂EDTA human plasma method aligned with ICH M10 is proposed.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Futuristic Publications

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
